A molecular perspective for the development of antibodies against the human respiratory syncytial virus

Simple item page
dc.contributor.authorLoaiza, Ricardo A.
dc.contributor.authorRamirez, Robinson A.
dc.contributor.authorSepulveda-Alfaro, Javiera
dc.contributor.authorRamirez, Mario A.
dc.contributor.authorAndrade, Catalina A.
dc.contributor.authorSoto, Jorge A.
dc.contributor.authorGonzalez, Pablo A.
dc.contributor.authorBueno, Susan M.
dc.contributor.authorKalergis, Alexis M.
dc.date.accessioned2025-01-20T17:08:47Z
dc.date.available2025-01-20T17:08:47Z
dc.date.issued2024
dc.description.abstractThe human respiratory syncytial virus (hRSV) is the leading etiologic agent causing respiratory infections in infants, children, older adults, and patients with comorbidities. Sixty-seven years have passed since the discovery of hRSV, and only a few successful mitigation or treatment tools have been developed against this virus. One of these is immunotherapy with monoclonal antibodies against structural proteins of the virus, such as Palivizumab, the first prophylactic approach approved by the Food and Drug Administration (FDA) of the USA. In this article, we discuss different strategies for the prevention and treatment of hRSV infection, focusing on the molecular mechanisms against each target that underly the rational design of antibodies against hRSV. At the same time, we describe the latest results regarding currently approved therapies against hRSV and the challenges associated with developing new candidates.
dc.fuente.origenWOS
dc.identifier.doi10.1016/j.antiviral.2023.105783
dc.identifier.eissn1872-9096
dc.identifier.issn0166-3542
dc.identifier.urihttps://doi.org/10.1016/j.antiviral.2023.105783
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/90983
dc.identifier.wosidWOS:001165464200001
dc.language.isoen
dc.revistaAntiviral research
dc.rightsacceso restringido
dc.subjectHuman respiratory syncytial virus
dc.subjectMonoclonal antibodies
dc.subjectImmunotherapy
dc.subjectTreatment
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleA molecular perspective for the development of antibodies against the human respiratory syncytial virus
dc.typeartículo
dc.volumen222
sipa.indexWOS
sipa.trazabilidadWOS;2025-01-12
Files
Collections
Artículos de revistas